/PRNewswire/ Nasus Pharma, a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) therapeutic solutions today.
Taffix® regains marketing approval in Spain prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Taffix® blocks the Delta Variant of SARS-CoV-2 in addition to the Alpha (UK) and Beta (South African) Variant prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(0)
TEL AVIV, Israel, April 21, 2021 /PRNewswire/ Nasus Pharma a privately held clinical-stage biopharmaceutical company developing a powder-based intranasal (PBI) product portfolio to address acute medical conditions and public health threats, today announced data from a collaborative in vitro study with the Central Virology Laboratory, Ministry of Health, Public Health Services, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, which demonstrated that the gel layer produced by Taffix powder after administration of a tissue culture infectious dose of the virus, effectively blocked 100% of the two new highly infective variants of SARS-CoV-2 virus ( the British and South African variants) as demonstrated by qt PCR testing of cells incubated with Taffix inoculated with the viruses.